Sildenafil Tablet, Film Coated
Product Images NDC 68001-597

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 68001-597). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image 01

Image 01
This is a medication called Sildenafil Tablets, which come in a film-coated tablet form. Each tablet contains 20mg of sildenafil citrate, a medication for treating erectile dysfunction. The usual dosage is to be determined by the prescribing information for Dosage and Administration. It should be stored between 20° to 25°C (68° to 77°F) and out of reach of children. It is manufactured by Macleods Pharmaceuticals Limited and distributed by BluePoint Laboratories.*
FDA Label Image

Sildenafil Label 20mg 90ct_rev 06-18 (Sildenafil 90s)

Sildenafil Label 20mg 90ct_rev 06-18 (Sildenafil 90s)
The text describes a medication called Sildenafil Tablets, USP with a concentration of 20mg/tablet. The medication should be stored at 20-25°C (68-77°F) with permitted excursions to 15-30°C (59-86°F) and dispensed in tight containers. Please see prescribing information for dosage and administration. The medication is manufactured for BluePoint Laboratories by Macleods Pharmaceuticals Ltd in Himachal Pradesh, India. Pharmacist should dispense the medication with the attached patient information leaflet and keep out of reach of children.*
FDA Label Image

Figure-10 (Sildenafil Fig 10)

Figure-10 (Sildenafil Fig 10)
FDA Label Image

Figure-11 (Sildenafil Fig 11)

Figure-11 (Sildenafil Fig 11)
FDA Label Image

Figure 12 (Sildenafil Fig 12)

Figure 12 (Sildenafil Fig 12)
The text provides a graph displaying the change from baseline in meters for different treatments at various study weeks. The treatments include Sildenafil at 1mg, 5mg, and 20mg TID. The graph shows the mean change from baseline with the Standard Error at each visit up to week 12.*
FDA Label Image

Fig-6 (Sildenafil Fig 6)

Fig-6 (Sildenafil Fig 6)
FDA Label Image

Fig-8 (Sildenafil Fig 8)

Fig-8 (Sildenafil Fig 8)
The text is a chart that shows recommendations on dose adjustments for interacting drugs, along with their fold change and 90% CI. The drugs are listed in alphabetical order, and some require adjustment while others do not. There are also asterisks indicating specific notes or warnings about certain drug interactions.*
FDA Label Image

Figure 9 (Sildenafil Fig 9)

Figure 9 (Sildenafil Fig 9)
FDA Label Image

Figure-7 (Sildenafil Figure 7)

Figure-7 (Sildenafil Figure 7)
This text appears to be a table that shows the drug fold change and %0% CI recommendation for various drugs. It provides information on the adjustment of doses for drugs such as Atorastin, Astromycn, Bosentan, Cimetidine, Evermyel, and Saquinavie. It also mentions that there is no need for dose adjustment when taking Oral Contraceptives. There is a note that co-administration of drugs with sildenafil is not recommended. However, the text also mentions that there is no benefit in adding sildenafil to bosentan therapy when it comes to exercise capacity. The table also includes a graph with a solid line at x=1, indicating a change in relation to sildenafil alone. Overall, this text appears to be a medical document providing information on drug interaction and recommendations.*
FDA Label Image

Str (Sildenafil Str)

Str (Sildenafil Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.